Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus SAXENDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus SAXENDA.
MOUNJARO (AUTOINJECTOR) vs SAXENDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Subcutaneously once weekly; initial dose 2.5 mg for 4 weeks, then increase to 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated; maximum 15 mg weekly.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
None Documented
None Documented
Terminal elimination half-life ~5 days (117 hours), supporting once-weekly dosing.
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Renal: negligible; Fecal: primarily via biliary elimination as intact peptide; total clearance ~0.056 L/h.
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist, Anti-obesity